Access the recording of a panel discussion with experts from industry, academia, and FDA on the problem and associated impact of biological sample issues in clinical trials

What Was Covered

It is estimated that a large amount of biological samples collected during clinical trials are lost, switched or otherwise unusable due to improper accessioning and handling. The aim of this webinar was to discuss the problem and associated impact across the drug development paradigm–study design, study conduct, data analysis, reporting, and regulatory review/approval.

•The prevalence of errors and impact of unusable samples (i.e., lost, improper handling or labeling)
•The importance of ethical considerations of the patients in the study design and sampling schema
•Downstream implications for the bioanalytical labs
•Regulatory impact of sample mishandling and loss